Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Medlab Clinical: Edison Open House Healthcare 2022

Medlab Clinical: Edison Open House Healthcare 2022

Medlab Clinical — 2 videos in collection

More on this equity

Medlab Clinical is an Australian biotechnology company that is developing therapeutics using its proprietary delivery platform NanoCelle. Its most advanced programme is in cancer pain management with lead drug candidate NanaBis, a medicinal cannabis product for cancer-related bone pain.

• Please tell us more about the recent change in focus from a nutraceutical to a biotech business.
• What is NanoCelle and what does it do?
• Are there any potential issues with the NanoCelle technology?
• What kind of compounds are you focusing on at present and what would you say is your leading contender?
• Do you think your Australian compassionate programme might be replicated in other countries?
• What are the timelines for the clinical development of NanaBis?
• Have you seen any impact on your workflow from COVID-19?
• Following the recent addition of the US patent for NanoCelle, what is your current patent portfolio?

< Previous
Next >

You may also be interested in these:

Healthcare

Medlab Clinical – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free